Table 1.
Baseline characteristics of patients initiating combination antiretroviral therapy by period of initiation
| 1996–99 (N=18 587) | 2000–02 (N=13 914) | 2003–05 (N=10 854) | |
|---|---|---|---|
|
Age (years)
| |||
| Median | 36 (31–43) | 37 (31–44) | 38 (32–45) |
| 16–29 years | 3106 (16·7%) | 2481 (17·8%) | 1935 (17·8%) |
| 30–39 years | 9039 (48·6%) | 5916 (42·5%) | 4181 (38·5%) |
| 40–49 years | 4248 (22·9%) | 3614 (26·0%) | 3123 (28·8%) |
| 50+ years | 2194 (11·8%) | 1903 (13·7%) | 1615 (14·9%) |
|
| |||
|
Sex
| |||
| Female | 4045 (21·8%) | 4133 (29·7%) | 3572 (32·9%) |
| Male | 14 542 (78·2%) | 9781 (70·3%) | 7282 (67·1%) |
|
| |||
|
Risk factor for transmission
| |||
| Injecting drug use | 3495 (18·8%) | 1836 (13·2%) | 910 (8·4%) |
| Other | 15 092 (81·2%) | 12 078 (86·8%) | 9944 (91·6%) |
|
| |||
|
CD4+ cell count (cells μL)
| |||
| <100 | 4848 (26·1%) | 4104 (29·5%) | 2769 (25·5%) |
| 100–199 | 3165 (17·0%) | 2943 (21·2%) | 2395 (22·1%) |
| ≥200 | 10 574 (56·9%) | 6867 (49·3%) | 5690 (52·4%) |
|
| |||
|
Clinical CDC stage
| |||
| A/B | 14 258 (76·7%) | 10 467 (75·2%) | 8576 (79·0%) |
| C | 4329 (23·3%) | 3447 (24·8%) | 2278 (21·0%) |
|
| |||
|
Plasma HIV RNA level (log10 copies per mL)
| |||
| <4·00 | 2533 (13·6%) | 1798 (12·9%) | 1439 (13·3%) |
| 4·00–4·99 | 7543 (40·6%) | 5403 (38·8%) | 4260 (39·3%) |
| ≥5·00 | 8511 (45·8%) | 6713 (48·3%) | 5155 (47·5%) |
|
| |||
|
Initial drug regimen
| |||
| PI-based | 14 530 (78·2%) | 5977 (43·0%) | 5375 (49·5%) |
| NNRTI-based | 3072 (16·5%) | 5547 (39·9%) | 4248 (39·1%) |
| Three NRTIs | 620 (3·3%) | 1994 (14·3%) | 969 (8·9%) |
| Other | 365 (2·0%) | 396 (2·8%) | 262 (2·4%) |
Data are median (IQR) or n (%). NNRTI=non-nucleoside reverse transcriptase inhibitor. NRTI=nucleoside reverse transcriptase inhibitor. PI=protease inhibitor.